Do Traders Think Progenity Inc (PROG) Can Keep Climbing Tuesday?

Tuesday, September 14, 2021 09:56 AM | InvestorsObserver Analysts

Mentioned in this article

Do Traders Think Progenity Inc (PROG) Can Keep Climbing Tuesday?

Overall market sentiment has been down on Progenity Inc (PROG) stock lately. PROG receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

Progenity Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on PROG!

See Full PROG Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With PROG Stock Today?

Progenity Inc (PROG) stock is trading at $1.12 as of 9:53 AM on Tuesday, Sep 14, a rise of $0.18, or 19.15% from the previous closing price of $0.94. The stock has traded between $1.07 and $1.20 so far today. Volume today is 11,694,244 compared to average volume of 9,701,807.

More About Progenity Inc

Progenity Inc is a biotechnology company. It is engaged in developing and commercializing molecular testing products as well as innovating in the field of precision medicine. It utilizes a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics, to molecular testing products and to the development of a suite of investigational ingestible devices and drug and device combinations designed to provide precise diagnostic sampling and drug delivery solutions. The firm generates its revenue from molecular laboratory tests, principally from the sale of Innatal, Preparent, and pathology molecular testing. The company's operations are carried out in the United States. Click Here to get the full Stock Report for Progenity Inc stock.